Characterization of Small Renal Tumors With Magnetic Resonance Elastography

Prezzi, Davide; Neji, Radhouène; Kelly-Morland, Christian; Verma, Hema; O’Brien, Tim; Challacombe, Ben; Fernando, A.; Chandra, Ashish; Sinkus, Ralph

doi:10.1097/rli.0000000000000449

Cited by 15 publications

(13 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recent feasibility study has demonstrated the usefulness of magnetic resonance elastography (MRE), as part of a multiparametric MR imaging protocol, to characterise 21 indeterminate SRM. MRE viscoelastic profile may discriminate between oncocytomas and clear cell RCC, and further prospective studies are warranted [ 67 ]. The emerging concept that biomedical images contain ‘hidden’ information about the underlying tissue biology that can be revealed via quantitative image analysis, an approach known as radiomics, has prompted the application of automated image analysis tools in renal tumours [ 68 ].…”

Section: Resultsmentioning

confidence: 99%

Imaging for the diagnosis and response assessment of renal tumours

et al. 2018

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

Imaging for the diagnosis and response assessment of renal tumours

et al. 2018

Self Cite

View full text Add to dashboard Cite

show abstract

“…In addition to anatomical and functional MRI, magnetic resonance elastography (MRE) have potential for characterization of small renal tumors (SRTs). [11] The diagnostic validity of MRE on metanephric adenoma may need more investigation.…”

Section: Discussionmentioning

confidence: 99%

Metanephric adenoma with low apparent diffusion coefficient value mimicking renal cell carcinoma

Chang

Ng²,

Wong³

et al. 2018

Medicine

View full text Add to dashboard Cite

Rationale:Metanephric adenoma (MA) is a rare and often benign tumor. Most MAs were misdiagnosed as renal cell carcinomas (RCCs) preoperatively. Diffusion weighted imaging (DWI) and apparent diffusion coefficient (ADC) mapping can help to differentiate benign and malignant tumors. However, there are still pitfalls in using DWI and ADC to discriminate benign and malignant lesions.Patient concerns:A 56-year-old woman had a right renal metanephric adenoma. The tumor showed very low ADC value preoperatively and was misdiagnosed as a renal cell carcinoma.Diagnosis:Intraoperative ultrasound-guided percutaneous biopsy of tumor was performed. Based on the histopathological findings and immunohistochemical stains, a diagnosis of metanephric adenoma was suggested.Interventions:The patient received percutaneous cryoablation of this tumor. Five years later, she underwent right partial nephrectomy because local recurrence was revealed on a follow-up computed tomography (CT).Outcomes:MA was confirmed again by histological examination. The patient was uneventful after surgery.Lessons:ADC mapping can be used for differentiating RCCs from other benign tumors by their lower ADC values. However, some benign and malignant lesions have overlapped low ADC values. This case illustrated that a benign lesion such as MA could mimic RCC on ADC, by its highly cellular component. Cryoablation is an optional treatment, which has an increased risk of local recurrence. Follow-up CT or MRI is useful and necessary for detection of local recurrence by depicting enhancing solid parts in a tumor over time.

show abstract

“…The underpinning experimental observation for the application of MRE to cancer is that malignancy increases stiffness through collagen deposition in the extracellular matrix and raises interstitial pressure levels from its abnormal vasculature . MRE has shown promising potential for the characterization of focal lesions (benign vs. malignant) in multiple organs, including the liver, breast, pancreas, and kidney . It may also serve as a potential biomarker of treatment resistance.…”

Section: Emerging Mri Biomarkersmentioning

confidence: 99%

“…72 MRE has shown promising potential for the characterization of focal lesions (benign vs. malignant) in multiple organs, including the liver, 73 breast, 74 pancreas, 75 and kidney. 76 It may also serve as a potential biomarker of treatment resistance.…”

Section: Emerging Mri Biomarkersmentioning

confidence: 99%